Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study. (2023). Biomolecules and Biomedicine, 23(6), 1089–1095. https://doi.org/10.17305/bb.2023.9253